Findings

What do systematic reviews say?

6 questions · 6 findings · 1 reviews · Gynaecological, Neuro-oncology and Orphan Cancer

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 3 · 50%Low 0 · 0%Moderate 3 · 50%High 0 · 0%

Large‐volume residual disease (LVRD) > 1 cm vs small‐volume residual disease (SVRD) < 1 cm

Progression‐free survival · women with advanced EOC after primary IDS

It is very uncertain whether large‐volume residual disease (LVRD) > 1 cm changes progression‐free survival: Median length of compared with small‐volume residual disease (SVRD) < 1 cm (very low certainty).

1 finding from 1 review

Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after… 2022 · Cochrane Headline outcomes only
HR 1.76 [1.23, 2.52]
4 studies · 1145 participants
Very low

Residual disease (RD) > 0 cm vs NMRD

Progression‐free survival · women with advanced EOC after primary IDS

It is very uncertain whether residual disease (RD) > 0 cm changes progression‐free survival: Median length of compared with NMRD (very low certainty).

1 finding from 1 review

Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after… 2022 · Cochrane Headline outcomes only
HR 1.36 [1.05, 1.76]
1 study · 471 participants
Very low

Small‐volume residual disease (SVRD) (< 1 cm) vs NMRD

Progression‐free survival · women with advanced EOC after PDS

Small‐volume residual disease (SVRD) < 1 cm probably leads to higher progression‐free survival: Median length of compared with NMRD (moderate certainty).

1 finding from 1 review

Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after… 2022 · Cochrane Headline outcomes only
HR 1.88 [1.63, 2.16]
10 studies · 6596 participants
Moderate

Large‐volume residual disease (LVRD) > 1 cm vs NMRD

Progression‐free survival · women with advanced ovarian cancer after PDS

Large‐volume residual disease (LVRD) > 1 cm probably leads to higher progression‐free survival: Median length of compared with no macroscopic residual disease (NMRD) (moderate certainty).

1 finding from 1 review

Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after… 2022 · Cochrane Headline outcomes only
HR 2.1 [1.84, 2.4]
6 studies · 2629 participants
Moderate

Large‐volume residual disease (LVRD) > 1 cm vs small‐volume residual disease (SVRD) < 1 cm

Progression‐free survival · women with advanced EOC after PDS

Large‐volume residual disease (LVRD) > 1 cm probably leads to higher progression‐free survival: Median length of compared with small‐volume residual disease (SVRD) < 1 cm (moderate certainty).

1 finding from 1 review

Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after… 2022 · Cochrane Headline outcomes only
HR 1.3 [1.08, 1.56]
2 studies · 3402 participants
Moderate

Small‐volume residual disease (SVRD) (< 1 cm) vs NMRD

Progression‐free survival · women with advanced EOC after primary IDS

1 finding from 1 review

Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after… 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 322 participants
Very low